
AI is playing a crucial role in revolutionizing biologic drug discovery, as highlighted by AstraZeneca's efforts to integrate AI into their R&D processes. By using AI to prioritize and design drug candidates, AstraZeneca is able to focus on the most promising molecules, reducing development timelines and costs. The company's 'lab of the future' in Cambridge, Massachusetts, combines AI with robotic automation to create a continuous discovery system. This approach not only speeds up the development process but also enables the exploration of new drug classes and targets previously considered untreatable.
Read originalEarlier coverage that leads up to this article, and what followed. Lines connect each piece to the closest one after it, converging here.
WIRED AI · April 29, 2026 · Background
TechCrunch AI · May 18, 2026 · Background
MIT News AI · May 20, 2026 · Related
OpenAI · June 17, 2026 · Related
AI News · July 3, 2026 · Background
The Verge AI · July 3, 2026 · Related
Crunchbase News · July 10, 2026 · Background
WIRED AI · July 12, 2026 · Background
AI News · August 3, 2026 · Related
The Rundown AI · August 7, 2026 · Background
TechCrunch AI · August 19, 2026 · Related
The Rundown AI · August 20, 2026 · Related
Sifted · September 18, 2026 · Background
AI Revolutionizes Biologic Drug Discovery
2 developments
© Cole MedinAnthropic’s latest research exposes a quiet but dangerous flaw in agentic workflows: experts follow AI recommendations 86% of the time, often adopting the agent's reasoning as their own. This isn't just about accuracy; it's about cognitive capture, where human oversight dissolves into passive compliance. The study shows that even when users believe they are steering, the agent’s framing dictates the outcome. Practitioners must now actively counter this bias by forcing agents to justify deviations or prototype alternatives before committing to a path. This shift demands a new discipline in how we interact with coding assistants. We can no longer assume our intent drives the result; the model's suggestion often becomes the default truth. The real work is ensuring we remain the architects, not just the approvers.
© WIRED AICisco Talos has uncovered a new infostealer strain that actively uses commercial LLMs to profile victims and prioritize high-value targets. Dubbed Volta-Autodoxer, the malware collects credentials and browsing data, then feeds this into models like Claude Opus 4.6 via OpenRouter to generate structured intelligence dossiers. This marks a shift from passive data theft to active, AI-driven triage, allowing attackers to bypass guardrails with fallback models like Kimi K2 or Gemini. The capability foreshadows a future where lower-sophistication criminals can execute sophisticated, targeted attacks at scale.
© Matt WolfeOpenAI researchers published findings disproving the Exponential Time Hypothesis, a major result in computational complexity theory.